Evaluating Sodium and Fluid Restrictions in Heart Failure Patients

Developments in the field of heart failure have led to increased available therapies, including medications, devices, and patient-driven interventions such as exercise and diet. In a recent review published in Progress in Cardiovascular Diseases, researchers evaluated the current state of evidence for dietary sodium and fluid restriction, two common interventions for heart failure patients. Over the […]

Read Article


Examining the Frequency of Gestational Diabetes Mellitus and Preeclampsia in Pregnancy

A recent study, published in Acta Obstetricia et Gynecologica Scandinavica, examined whether rates of gestational diabetes mellitus (GDM), a type of diabetes that emerges during pregnancy, and preeclampsia, a complication linked to high blood pressure that typically develops after 20 weeks of pregnancy, are on the rise. Both of these conditions can result in serious health […]

Read Article


Assessing the Benefit of Accelerometer Data in the Management of Heart Failure

A central goal in the management of heart failure (HF) is to improve patient health status and functional capacity, characterized by the ability to perform tasks and activities essential to day-to-day living. Two common tools used to measure health status and functional capacity in HF are the Kansas City Cardiomyopathy Questionnaire-Physical Limitation Score (KCCQ-PLS), a […]

Read Article


2023 CVC Annual Report – Building Blocks: Shaping our Future

We are pleased to share the 2023 Canadian VIGOUR Centre (CVC) annual report. The theme of the report—Building Blocks: Shaping Our Future—embodies the CVC’s commitment to generating new knowledge that will inform future directions of cardiovascular research in Canada and around the world. Our vision, mission, and core values are, in many ways, the foundational […]

Read Article


Iron Deficiency, Anemia, and Iron Supplementation in Patients With Heart Failure

Studies have demonstrated there is a correlation between iron deficiency (ID) and clinical outcomes in patients with heart failure, regardless of whether or not they have ID anemia (IDA). Treatment of ID in heart failure has been investigated in a number of recent trials (including AFFIRM-AHF, IRONMAN, and HEART-FID), and their findings have led to guidelines recommendations for […]

Read Article


Empagliflozin Following a Heart Attack: Results from the EMPACT-MI Trial

Empagliflozin, a medication used to manage and treat type 2 diabetes, is known to improve cardiovascular outcomes in patients with heart failure, chronic kidney disease, or type 2 diabetes with high cardiovascular risk. Published in the New England Journal of Medicine and simultaneously presented at the American College of Cardiology’s Annual Scientific Session in April […]

Read Article


Apolipoprotein A1 Infusions to Facilitate Cholesterol Efflux Following a Heart Attack: Results from the AEGIS-II Trial

CSL112 is an apolipoprotein A1 (apoA-I) derived from human plasma, and is a component of high-density lipoprotein (HDL, known as the “good”) cholesterol. CSL112 removes plaque from the arteries, and helps facilitate the removal process (cholesterol efflux) of low-density lipoprotein (LDL, known as the “bad”) cholesterol from the body. Published in the New England Journal […]

Read Article


CVC Cardiovascular Health Foundation Announces Newly Endowed Chair in Cardiovascular Science

On Monday, March 18th, 2024 The CVC Cardiovascular Health Foundation (CVCF) announced a $5-millon donation that will fund a new research chair in cardiovascular science in the Faculty of Medicine & Dentistry (FoMD).  In addition to supporting critical advancements in research and health outcomes for patients, this initiative will foster collaborative engagement across disciplines within […]

Read Article


Gestational Diabetes: One Size Does Not Fit All

Gestational diabetes (GDM) is a type of diabetes that develops during pregnancy, and although it generally resolves after delivery, it has been associated with long-term health issues for both mothers and their babies. Rates of GDM are rising globally. Current professional guidelines differ on how to best diagnose and treat GDM, which is in part […]

Read Article


Evaluating a Pharmacoinvasive Approach in STEMI Patients with Cardiogenic Shock and Prolonged Interhospital Transport Times

ST-elevation myocardial infarction (STEMI) occurs when a coronary artery is completely blocked. A known complication in approximately 6-10% of STEMI patients is cardiogenic shock, a condition that develops when the heart is unable to pump enough blood to the brain and other key organs in the body. The standard best practice approach for patients with […]

Read Article


Dr. Jacob Udell Joins the CVC as a Senior Associate Faculty Member

The CVC is pleased to welcome Dr. Jacob Udell as a Senior Associate Faculty Member. Dr. Udell is the Division Head of Cardiology at the Women’s College Hospital, and Director of the Peter Munk Clinical Trials and Translation Unit at Toronto General Hospital. He is also an Associate Professor of Medicine at the University of […]

Read Article


How Does Age Impact Complete Revascularization in Patients with STEMI?

The COMPLETE trial demonstrated that a treatment strategy of staged complete revascularization, consisting of angiography-guided percutaneous coronary intervention (PCI, a minimally invasive procedure to open a blocked artery) of all suitable nonculprit lesions, reduced the number of major cardiovascular (CV) events when compared to culprit-lesion-only PCI in STEMI patients with multivessel disease. In this subgroup analysis of the […]

Read Article


Do Heart Failure Biomarkers Influence Heart Failure Treatment Response?

Heart failure (HF) is one of the leading causes of cardiac disease, death, and poor quality of life, and impacts approximately 26 million people worldwide. The frequency and seriousness of this condition emphasizes the importance of quick and accurate diagnosis, management, and treatment of HF. Emerging understanding about the cellular and molecular pathways of HF […]

Read Article


Winter 2023 Chronicle Newsletter

We are pleased to share the Winter 2023 issue of the Canadian Cardiac Chronicle newsletter. Highlights from this issue include: Read and subscribe to the newsletter here.

Read Article


Current and Future Insights from the VICTORIA Trial

Heart failure with reduced ejection fraction (HFrEF), one of the leading causes of heart-related deaths worldwide, occurs when the heart is not able to effectively pump enough blood to meet the body’s needs. The VICTORIA trial examined the effects of vericiguat (a novel first in class drug used to reduce the risk of death and […]

Read Article


Long-Term Safety and Efficacy of Alirocumab in Patients Post-Acute Coronary Syndrome

Although lipid-lowering therapy is frequently used as a long-term (typically lifetime) intervention to reduce cardiovascular risk, research on the efficacy and safety of this treatment strategy is often limited to the relatively short time frame of clinical trials (typically 2-5 years).  Alirocumab is an injectable monoclonal antibody directed against proprotein convertase subtilisin/kexin type 9 (PCSK9) that […]

Read Article




Age, Sex, and Outcomes in Heart Failure With Reduced Ejection Fraction

Age and sex are both factors in the treatment and outcomes of patients with heart failure (HF). Current research shows that women and older patients are under-represented in HF clinical trials, and as a result, guideline recommendations are largely based on data from men.   Published in JACC: Heart Failure, this secondary analysis of the VICTORIA trial […]

Read Article


Frailty: A New Vital Sign in Heart Failure Comes of Age

Frailty is a state of reduced physiological capacity across multiple body systems that increases vulnerability and poor health outcomes in older adults. Although frailty is common, particularly amongst people with cardiovascular disease, it often goes unrecognized. In a recent companion editorial published in the European Heart Journal (referring to the article ‘Frailty and outcomes in heart failure patients […]

Read Article